# A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

> **NCT03042611** · PHASE3 · COMPLETED · sponsor: **Elevar Therapeutics** · enrollment: 460 (actual)

## Conditions studied

- Gastric Cancer
- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Rivoceranib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03042611
- **Lead sponsor:** Elevar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-14
- **Primary completion:** 2019-02-15
- **Final completion:** 2020-09-23
- **Target enrollment:** 460 (ACTUAL)
- **Last updated:** 2022-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03042611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03042611, "A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03042611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*